Navigation Links
Bionanomachines -- proteins as resistance fighters
Date:8/14/2009

A Dresden research team used laser tweezers to measure the friction between a single motor protein molecule and its track. The team found that also within our cells, motors work against the resistance of friction and are restrained in its operationusually by far not as much though as their macroscopic counterparts. These first experimental measurements of protein friction could help researchers to better understand key cellular processes such as cell division which is driven by such molecular machines.

Friction is the force that resists the relative motion of two bodies in contact. The same is true on the nanoscale: Molecular motors have to fight the friction created between them and their tracks. However, since the frictional forces acting on such motors had not been measured before, it was not known how they depend on the speed and the direction of motion.

Friction Slows Down Proteins

Scientists in Dresden at the Biotechnology Center (BIO-TEC) of the Technical University of Dresden and at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) immobilized the molecular motor kinesin on a microsphere which was held by laser tweezers and dragged over its track, a so-called microtubule. In this manner, the friction force between the motor and its microtubule track was measured very precisely. "Just like for macroscopic machines, protein friction limits the speed and efficiency of the small bio-motors", says Erik Schffer, group leader at the BIOTEC and Jonathon Howard, director and group leader at the MPI-CBG.

The researchers explain that the protein, in the absence of an energy source, takes eight nanometer (a millionth of a millimeter) wide "diffusive hops", corresponding to the length of the tubulin subunits that make up a microtubule. The motors step from one tubulin subunit to the adjacent one by forming a new bond with the microtubule filament as another bond is broken. When pulled by the tweezers, the
'/>"/>

Contact: Florian Frisch
frisch@mpi-cbg.de
49-035-121-02840
Max-Planck-Gesellschaft
Source:Eurekalert

Page: 1 2

Related biology news :

1. Proteins in gel
2. Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease
3. TRAPping proteins that work together inside living cells
4. Pliable proteins keep photosynthesis on the light path
5. Autopilot guides proteins in brain
6. New method for detection of phosphoproteins reveals regulator of melanoma invasion
7. New high-throughput screening technique makes probing puzzling proteins possible
8. Scripps research scientists watch as individual alpha-synuclein proteins change shape
9. Inactivity of proteins behind longer shelf life when freezing
10. Caltech and UCSD researchers shed light on how proteins find their shapes
11. Inhibiting proteins may prevent cartilage breakdown in arthritis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... 16 CEL-SCI Corporation (NYSE Amex: ... prevention and treatment of infectious diseases and a late-stage oncology ... (FDA) has indicated that the Company can proceed with its ... LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 ...
... , , EAST BRUNSWICK, N.J. Sept. 16 ... on September 14, 2009, the Company completed a Type A meeting with ... Letter (CRL) received by Savient on July 31, 2009 regarding the Company,s ... gout in patients refractory to conventional therapy. , ...
... ... FDA, including increased scrutiny of complex medical devices, automating your QA process is more ... one of the leading medical device software engineering and QA consulting firms in the ... , ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: